Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age

NCT06592794 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT06592794
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06592794 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Observer-blinded, Placebo-controlled Study to Evaluate the Safety and Efficacy of mRNA-1403, a Multivalent Candidate Vaccine to Prevent Norovirus Acute Gastroenteritis in Adults ≥18 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 24, 2024
Completion date
February 15, 2027
Enrollment
37,864 (actual)
Sites
283

Conditions

As the registry lists them; a condition with its own page is linked.

acute gastroenteritis, norovirus acute gastroenteritis